/BIOA

BIOA Stock - BioAge Labs, Inc.

Q: What is the analyst price target for BIOA?

Analyst price target information is not currently available for BIOA.

Q: What is BIOA's market cap?

Market capitalization information is not currently available for BIOA.

Healthcare|Biotechnology|NASDAQ

$20.69+15.91%

+$2.84 (+15.91%) • Jan 13

GoAI Score

Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.

HOLD

Medium Confidence

Momentum

Momentum Score

Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.

100

Sentiment

Sentiment Score

Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).

Risk Score

Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.

Price Target

Average analyst price target from the last quarter. Shows expected upside/downside from current price.

+-42.0%upside

Target: $12.00

AI Analysis PreviewPremium

Real-time AI-powered market analysis

Precise entry/exit price targets

Risk assessment & position sizing

Unlock GoAI Insights for BIOA

Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.

Buy/Sell Signals

94% win rate on Alpha signals

Deep Analysis

Institutional-grade thesis

Real-Time Alerts

SMS & push notifications

Risk Scoring

Multi-factor analysis

Free 14-day trial • No credit card required

Financial Statements

Revenue & Profitability Trend

FY2022

FY2023

FY2024

Revenue

Net Income (Profit)

Net Loss

Key Metrics

Market CapN/A

P/E RatioN/A

Beta1.40

52W High$21.18

52W Low$2.88

Avg VolumeN/A

Income Statement (Fiscal Year)

Metric	FY2024	FY2023	FY2022
Revenue	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A
Gross Margin	N/A	N/A	N/A
Operating Income	$-78,194,000	$-48,400,000	$-39,969,000
Net Income	$-71,109,000	$-63,854,000	$-39,722,000
Net Margin	N/A	N/A	N/A
EPS	$-6.63	$-8.55	$-5.32

Company Overview

BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets based on insights into molecular changes that drive aging. Its product includes azelaprag, an orally available small molecule that is in phase 1 clinical trial for the treatment of obesity; and initiated phase 2 clinical trial of azelaprag in combination with tirzepatide for the treatment of obesity in older adults. It also develops BGE-100, an orally available small molecule brain-penetrant NLRP3 antagonist for the treatment of diseases driven by neuroinflammation. The company was incorporated in 2015 and is based in Richmond, California.

Visit Website

Earnings History & Surprises

BIOA

Beat Rate

40%

Last 5 quarters

Avg Surprise

-206.0%

EPS vs Estimate

Beats / Misses

2/3

Last 12 quarters

Latest EPS

$-0.56

Q4 2025

EPS Surprise History

Q4 23

No data

Q1 24

No data

Q3 24

No data

Q4 24

-830.6%

$-6.70vs$-0.72

Q1 25

-239.7%

$-1.97vs$-0.58

Q2 25

+30.8%

$-0.36vs$-0.52

Q3 25

-7.1%

$-0.60vs$-0.56

Q4 25

+16.4%

$-0.56vs$-0.67

Beat Estimate

Missed Estimate

Quarterly EPS Details

Period	Report Date	Estimated EPS	Actual EPS	Surprise	Result
Q1 2026	Mar 19, 2026	$-1.01	—	—	—
Q4 2025	Nov 6, 2025	$-0.67	$-0.56	+16.4%	✓ BEAT
Q3 2025	Aug 6, 2025	$-0.56	$-0.60	-7.1%	✗ MISS
Q2 2025	May 6, 2025	$-0.52	$-0.36	+30.8%	✓ BEAT
Q1 2025	Mar 20, 2025	$-0.58	$-1.97	-239.7%	✗ MISS
Q4 2024	Nov 7, 2024	$-0.72	$-6.70	-830.6%	✗ MISS
Q3 2024	Sep 26, 2024	—	$-1.80	—	—
Q1 2024	Mar 31, 2024	—	$-1.74	—	—
Q4 2023	Dec 31, 2023	—	$-2.81	—	—
Q3 2023	Sep 30, 2023	—	$-1.96	—	—
Q2 2023	Jun 30, 2023	—	$-2.30	—	—
Q1 2023	Mar 31, 2023	—	$-1.48	—	—
Q1 2018	Mar 27, 2018	$-0.72	—	—	—